Brief: Herantis Pharma Completes Patient Treatments In Main Study Of Phase 1-2 CDNF Trial In Parkinson's Disease

Herantis Pharma Oyj

19/12/2019 14:05

Dec 19 (Reuters) - Herantis Pharma Oyj  HRTIS.HE :
    * HERANTIS PHARMA PLC COMPLETES PATIENT TREATMENTS IN MAIN
STUDY
OF PHASE 1-2 CDNF TRIAL IN PARKINSON'S DISEASE
    * EXPECTS TO ANNOUNCE INITIAL DATA FROM MAIN STUDY IN Q1 OF
2020
    * EXTENSION STUDY, WHICH IS EXPECTED TO BE COMPLETED LATEST
IN
Q3/2020, IS FOLLOWED BY A LONG-TERM FOLLOW-UP STUDY

Source text for Eikon:  ID:nWkr6GfLfG 
Further company coverage:  HRTIS.HE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))